RxDoctor Payments DataLook up a doctor →

Meredith Berger, MD

Endocrinology, Diabetes & Metabolism · Midlothian, VANPI 1831181734

Payments from drug & device makers

$31,600in general payments, 2019–2025

Across 765 payments — averaging $41.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$18K
  • Lilly USA, LLC$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • Abbott$812
  • Insulet Corporation$720
  • plus $8K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi-aventis U.S. LLC52$17,985
Lilly USA, LLC84$1,575
Amgen(2 entities)65$1,398
Novo Nordisk81$1,154
Abbott51$812
Insulet Corporation20$720
Amneal Pharmaceuticals LLC37$576
Radius Health, Inc.19$530
AstraZeneca(2 entities)29$458
Novartis22$453
IBSA Pharma Inc.21$449
Boehringer Ingelheim25$445
AbbVie25$396
Antares Pharma, Inc.19$389
Xeris Pharmaceuticals, Inc.19$371
Dexcom, Inc.13$269
Medtronic(2 entities)10$251
Tandem Diabetes Care, Inc.9$249
Lifescan, Inc.12$228
Recordati_rare_diseases_inc.11$215
Merck12$195
Amarin Pharma, Inc.9$180
Bayer10$177
Mannkind Corporation8$156
Esperion Therapeutics, Inc.9$155
Tolmar, Inc.9$149
Pfizer7$141
Cequr Corporation3$133
Shire North American Group Inc7$111
Ascendis Pharma Endocrinology Inc6$99
Sequel Med Tech, LLC4$97
Clarus Therapeutics Inc.7$86
Astellas Pharma US Inc3$82
Currax Pharmaceuticals LLC5$71
Johnson & Johnson3$52
BETA Bionics, Inc.2$52
Ultragenyx Pharmaceutical Inc.3$51
Averitas Pharma Inc.2$48
Kyowa Kirin, Inc.2$48
Nevro Corp.2$47
Boston Scientific2$40
Valeritas, Inc.1$38
Corcept Therapeutics2$37
AMAG Pharmaceuticals, Inc.2$36
Metuchen Pharmaceuticals2$35
Zealand Pharma US, Inc.2$34
Kowa Pharmaceuticals America, Inc.2$32
Biohaven Pharmaceutical Holding Company Ltd.1$31
Inspire Medical Systems, Inc.1$30
Madrigal Pharmaceuticals1$25
Neurocrine Biosciences, Inc.1$22
Soleno Therapeutics, Inc.1$21
Acella Pharmaceuticals, LLC1$20
Ipsen Biopharmaceuticals, Inc1$19
EUSA Pharma (US) LLC1$18
Vifor Pharma, Inc.1$18
Nalpropion Pharmaceuticals LLC1$18
Amryt Pharma Holdings Ltd1$17
Vistapharm, Inc.1$15
Takeda Pharmaceuticals U.S.A., Inc.1$15

How this compares

$31,600 in reported general payments places this provider in the 85th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.

See all endocrinology, diabetes & metabolism providers in Virginia →

Medicare billing

Part B allowed, 2024
$349,136
Medicare patients
710
Services billed
6,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Midlothian

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →